Craig L. Leonardi

21.3k total citations · 11 hit papers
133 papers, 14.1k citations indexed

About

Craig L. Leonardi is a scholar working on Immunology, Dermatology and Epidemiology. According to data from OpenAlex, Craig L. Leonardi has authored 133 papers receiving a total of 14.1k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Immunology, 54 papers in Dermatology and 19 papers in Epidemiology. Recurrent topics in Craig L. Leonardi's work include Psoriasis: Treatment and Pathogenesis (96 papers), Dermatology and Skin Diseases (45 papers) and Autoimmune and Inflammatory Disorders Research (18 papers). Craig L. Leonardi is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (96 papers), Dermatology and Skin Diseases (45 papers) and Autoimmune and Inflammatory Disorders Research (18 papers). Craig L. Leonardi collaborates with scholars based in United States, Canada and Germany. Craig L. Leonardi's co-authors include Kenneth B. Gordon, Kim Papp, Alice B. Gottlieb, Alan Menter, Mark Lebwohl, Richard G. Langley, Robert Matheson, Alexa B. Kimball, Cynthia Guzzo and Newman Yeilding and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Craig L. Leonardi

129 papers receiving 13.7k citations

Hit Papers

Efficacy and safety of us... 2003 2026 2010 2018 2008 2008 2003 2005 2012 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
    2008 1.4k citations Craig L. Leonardi, Alexa B. Kimball et al. profile →
  2. Guidelines of care for the management of psoriasis and psoriatic arthritis
    2008 964 citations Alan Menter, Alice B. Gottlieb et al. Journal of the American Academy of Dermatology profile →
  3. Etanercept as Monotherapy in Patients with Psoriasis
    2003 935 citations Craig L. Leonardi, Bernard S. Goffe et al. profile →
  4. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
    2005 852 citations Stephen K. Tyring, Alice B. Gottlieb et al. profile →
  5. Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
    2012 741 citations Craig L. Leonardi, Claus Zachariae et al. profile →
  6. Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
    2012 729 citations Kim Papp, Craig L. Leonardi et al. profile →
  7. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    2007 695 citations Alan Menter, Stephen K. Tyring et al. Journal of the American Academy of Dermatology profile →
  8. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    2016 650 citations Kenneth B. Gordon, Andrew Blauvelt et al. profile →
  9. Guidelines of care for the management of psoriasis and psoriatic arthritis
    2008 612 citations Alice B. Gottlieb, Kenneth B. Gordon et al. Journal of the American Academy of Dermatology profile →
  10. A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
    2007 588 citations Richard G. Langley, Craig L. Leonardi et al. profile →
  11. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
    2015 483 citations Kim Papp, Kristian Reich et al. Journal of the American Academy of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Craig L. Leonardi United States 45 11.4k 6.4k 2.6k 2.0k 2.0k 133 14.1k
Kenneth B. Gordon United States 61 13.8k 1.2× 7.7k 1.2× 3.3k 1.2× 2.5k 1.2× 2.2k 1.1× 206 16.7k
Bruce Strober United States 53 7.6k 0.7× 5.1k 0.8× 2.0k 0.7× 1.6k 0.8× 1.2k 0.6× 285 11.1k
Cynthia Guzzo United States 41 8.8k 0.8× 3.9k 0.6× 2.7k 1.0× 1.4k 0.7× 1.1k 0.6× 84 12.5k
Ulrich Mrowietz Germany 60 7.5k 0.7× 5.9k 0.9× 1.4k 0.5× 1.5k 0.7× 1.4k 0.7× 331 12.7k
Alan Menter United States 80 19.1k 1.7× 12.2k 1.9× 4.7k 1.8× 3.5k 1.7× 3.3k 1.6× 387 25.4k
Gerald G. Krueger United States 52 7.7k 0.7× 3.6k 0.6× 3.1k 1.2× 1.1k 0.5× 1.0k 0.5× 121 9.9k
Wolf‐­Henning Boehncke Germany 55 8.7k 0.8× 4.4k 0.7× 2.7k 1.0× 1.3k 0.6× 1.4k 0.7× 356 13.2k
Paolo Gisondi Italy 49 5.8k 0.5× 3.3k 0.5× 2.5k 0.9× 975 0.5× 782 0.4× 285 8.7k
E.M.G.J. de Jong Netherlands 46 4.3k 0.4× 3.4k 0.5× 1.2k 0.5× 1.3k 0.6× 698 0.4× 315 7.6k
Jashin J. Wu United States 42 4.9k 0.4× 2.9k 0.5× 1.6k 0.6× 804 0.4× 847 0.4× 375 7.6k

Countries citing papers authored by Craig L. Leonardi

Since Specialization
Citations

This map shows the geographic impact of Craig L. Leonardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig L. Leonardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig L. Leonardi more than expected).

Fields of papers citing papers by Craig L. Leonardi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig L. Leonardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig L. Leonardi. The network helps show where Craig L. Leonardi may publish in the future.

Co-authorship network of co-authors of Craig L. Leonardi

This figure shows the co-authorship network connecting the top 25 collaborators of Craig L. Leonardi. A scholar is included among the top collaborators of Craig L. Leonardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig L. Leonardi. Craig L. Leonardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gulliver, Wayne, Kyoungah See, Baojin Zhu, et al.. (2023). Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry. PubMed. 8(2). 74–82.
2.
Hawkes, Jason E., Kyoungah See, Russel Burge, et al.. (2021). Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis. Dermatology and Therapy. 11(4). 1107–1118. 1 indexed citations
3.
Muzumdar, Sonal, Craig L. Leonardi, & Bruce Strober. (2021). Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series. 6(2). 93–98. 2 indexed citations
4.
Leonardi, Craig L., Kyoungah See, Gaia Gallo, et al.. (2021). Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool. Dermatology and Therapy. 11(4). 1249–1263. 11 indexed citations
5.
Lebwohl, Mark, Craig L. Leonardi, Nehal N. Mehta, et al.. (2020). Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). Journal of the American Academy of Dermatology. 84(2). 398–407. 19 indexed citations
6.
Leonardi, Craig L., Solmaz Setayeshgar, Sisi Wang, et al.. (2020). 14216 Long-term treatment effects of ixekizumab among psoriasis patients who achieved early high-level treatment outcomes in a real-world setting: Results from a single US dermatology referral practice. Journal of the American Academy of Dermatology. 83(6). AB133–AB133. 2 indexed citations
7.
Zachariae, Claus, Kenneth B. Gordon, Alexa B. Kimball, et al.. (2018). Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. Journal of the American Academy of Dermatology. 79(2). 294–301.e6. 25 indexed citations
8.
Gordon, Kenneth B., Craig L. Leonardi, Daniel E. Fürst, et al.. (2017). Highlights of Skin Disease Education Foundation’s 41st Annual Hawaii Dermatology SeminarTM. Seminars in Cutaneous Medicine and Surgery. 36(3S). S52–S59. 1 indexed citations
9.
Reich, Kristian, Craig L. Leonardi, Kim Papp, et al.. (2017). Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis”. Journal of Investigative Dermatology. 137(12). 2642–2644. 2 indexed citations
10.
Leonardi, Craig L. & Kenneth B. Gordon. (2014). New and Emerging Therapies in Psoriasis. Seminars in Cutaneous Medicine and Surgery. 33(2S). S37–S41. 10 indexed citations
11.
Pariser, David M., Craig L. Leonardi, Kenneth B. Gordon, et al.. (2011). Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis. Journal of the American Academy of Dermatology. 67(2). 245–256. 65 indexed citations
12.
13.
Leonardi, Craig L., Darryl Toth, Jennifer Clay Cather, et al.. (2006). A Review of Malignancies Observed during Efalizumab (Raptiva®) Clinical Trials for Plaque Psoriasis. Dermatology. 213(3). 204–214. 37 indexed citations
14.
Gottlieb, Alice B., Craig L. Leonardi, Bernard S. Goffe, et al.. (2006). Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database. Journal of the American Academy of Dermatology. 54(3). S92–S100. 57 indexed citations
15.
Leonardi, Craig L., et al.. (2005). Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Final phase IIIb study results. Journal of the American Academy of Dermatology. 52(3). P1–P1. 9 indexed citations
16.
Leonardi, Craig L., et al.. (2005). Results of a phase 2 dose-ranging and safety extension study of a novel oral fumarate, BG-12, in patients with severe psoriasis. Journal of the American Academy of Dermatology. 52(3). P193–P193. 1 indexed citations
17.
Leonardi, Craig L., et al.. (1995). Concurrent herpes simplex and varicella-zoster infection in an immunocompromised patient. Journal of the American Academy of Dermatology. 33(1). 126–129. 8 indexed citations
18.
Skinner, Robert B., William H. Light, Craig L. Leonardi, George F. Bale, & E. William Rosenberg. (1995). In vitro effects of benzodiazepines against leishmania mexicana amazoniensis and trypanosoma cruzi.. Journal of Investigative Dermatology. 4(104). 686. 2 indexed citations
19.
Zhu, Wen‐Yuan, et al.. (1993). Human papillomavirus DNA in the dermis of condyloma acuminatum. Journal of Cutaneous Pathology. 20(5). 447–450. 1 indexed citations
20.
Nahass, George T., Andrew Blauvelt, Craig L. Leonardi, & Neal S. Penneys. (1992). Basal cell carcinoma of the scrotum. Journal of the American Academy of Dermatology. 26(4). 574–578. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth B. Gordon Breakdown of academic impact, for papers by Bruce Strober Breakdown of academic impact, for papers by Cynthia Guzzo Breakdown of academic impact, for papers by Ulrich Mrowietz Breakdown of academic impact, for papers by Alan Menter Breakdown of academic impact, for papers by Gerald G. Krueger Breakdown of academic impact, for papers by Wolf‐­Henning Boehncke Breakdown of academic impact, for papers by Paolo Gisondi Breakdown of academic impact, for papers by E.M.G.J. de Jong Breakdown of academic impact, for papers by Jashin J. Wu
Rankless by CCL
2026